Clinical trial
ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic…
NCT00110084 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00110084 |
|---|---|
| Title | ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer |
| Official title | Phase II Trial of Weekly Nab (Nanoparticle Albumin Bound)-Paclitaxel (Nab-paclitaxel) (Abraxane®) in Combination With Gemcitabine in Patients With Metastatic Breast Cancer |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Paclitaxel protein-bound particles for injectable suspension (albumin-bound) |
| Enrollment | 50 |
| Start date | Aug 1, 2005 |
| Primary completion | May 1, 2010 |
| Completion | Aug 1, 2010 |
| First posted | May 4, 2005 |
| Last update posted | Jun 2, 2011 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: